| Bioactivity | Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease[1][2]. |
| Name | Miglustat hydrochloride |
| CAS | 210110-90-0 |
| Formula | C10H22ClNO4 |
| Molar Mass | 255.74 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
| Reference | [1]. Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm, 2011. 8(6): p. 2390-7. [2]. van Giersbergen, P.L. and J. Dingemanse, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol, 2007. 47(10): p. 1277-82. [3]. Miglustat. Mother To Baby | Fact Sheet, Organization of Teratology Information Specialists (OTIS), 1 April 2021. [4]. Neal J Weinreb, et al. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9. |
Miglustat hydrochloride
CAS: 210110-90-0 F: C10H22ClNO4 W: 255.74
Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active ceramide glucosyltransferase inhibitor. Miglustat
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.